Release Date: 2024-03-25

Tuberculosis Pleurisy

Murat Kilic (Author)

Release Date: 2024-03-25

Tuberculosis (TB) is the most common infectious disease that will cause death worldwide by 2022, apart from Covid-19. More than 10 million people are infected each year, and half of untreated cases can be fatal. TB usually affects the lungs and is transmitted through the air. Extrapulmonary TB develops in 25% of cases and usually [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inThoracic Infections
First Page95
Last Page104
DOIhttps://doi.org/10.69860/nobel.9786053358930.9
ISBN978-605-335-893-0 (PDF)
LanguageENG
Page Count10
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Tuberculosis (TB) is the most common infectious disease that will cause death worldwide by 2022, apart from Covid-19. More than 10 million people are infected each year, and half of untreated cases can be fatal. TB usually affects the lungs and is transmitted through the air. Extrapulmonary TB develops in 25% of cases and usually occurs within 6-12 weeks of primary infection. Tuberculosis is a widespread health problem in low- and middle-income countries. Lymph node is the most common form of TB after tuberculosis. Tuberculosis pleurisy usually occurs as a complication of lung tuberculosis. The pleural cavity contains a small amount of fluid and is held in a constant volume by the lymphocytes in the pleural layers. Some untreated cases of lung tuberculosis can recover by themselves, while others can turn into extrapulmonary forms over time. Early diagnosis and treatment are important in preventing these conditions. The diagnosis highlights the importance of traditional methods such as tuberculin skin test (TDT) and measurement of ADA levels, as well as increased IFN-γ levels in recent years. A pleural biopsy is an important method to confirm the presence of granulomatous inflammation, which is to be specific to tuberculosis. In patients who do not respond to treatment or cannot rule out alternative diagnoses, therapeutic toracenthesis or drainage with pleural catheters may be required. In patients with pleurisy of locular tuberculosis, the use of intrapleuric fibrinolytic agents has been shown to have a positive effect on lung volume. Treatment lasts for at least six months and patients with symptomatic effusion can be drained with therapeutic toracenthesis or pleural catheters. The effect of corticosteroid use remains to be discussed. These methods enable a diagnosis and a faster and more effective treatment to be initiated.

Murat Kilic (Author)
Inonu University
https://orcid.org/0000-0001-7500-8478
3Asistant Prof. Dr. Murat Kılıç is a scientist with a professional career of more than 20 years and has made original contributions in the field of Thoracic Surgery. His work has led to the publication of more than 48 research articles, oral and poster presentations. He has worked as a hospital administrator and Hospital administrator in various hospitals and as a Dr. Lecturer at the University of Health Sciences. He worked as a Dr. Lecturer at the University of Health Sciences. He is currently working as a Thoracic Surgeon at Malatya Inonu University Turgut Özal Medical Center.

  • Valdes L, Alvarez D, Valle JM, Pose A, San José E. Th e etiology of pleural eff usions in an area with high incidence of tuberculosis. Chest. 1996;109(1):158-62.

  • Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One. 2011;6(4):e17601.

  • Vorster MJ, Allwood BW, Diacon AH, Koegelenberg CF. Tuberculous pleural eff usions: advances and controversies. J Th orac Dis. 2015;7(6):981–991.

  • Allen JC, Apicella MA. Experimental pleural eff usion as a manifestation of delayed hypersensitivity to tuberculin PPD. J Immunol 1968; 101(3): 481-7.

  • Özkan S. Tüberküloz plörezi ve tüberküloz lenfadenit. Klinik Gelişim 2007; 20: 19-23.

  • Porcel JM. Tuberculous pleural eff usion. Lung. 2009; 187(5): 263–70.

  • Taylan M, Demir M, Yilmaz S, Kaya H, Sen H, S, Oruc M, et al. Eff ect of human development index parameters on tuberculosis incidence in Turkish provinces. J. Infect. Dev. Ctries. 2016, 10, 1183–1190.

  • Wang XJ, Yang Y, Wang Z, et al. Effi cacy and safety of diagnostic thoracoscopy in undiagnosed pleural eff usions. Respiration 2015;90(3):251-5.

  • Wang NS. Th e preformed stomas connecting the pleural cavity and the lymphatics in the parietal pleura. Am Rev Respir Dis 1975; 111(1): 12-20.

  • Porcel JM. Tuberculous pleural eff usion. Lung. 2009; 187(5):263-70.

  • Valdes L, Alvarez D, San José E, Penela P, et al. A. Tuberculous pleurisy: a study of 254 patients. Arch Intern Med. 1998 12;158(18):2017-21.

  • Wang Z, Xu LL, Wu YB, et al. Diagnostic value and safety of medical thoracoscopy in tuberculous pleural eff usion. Respir Med 2015; 109(9): 1188–92.

  • Macias A, Sanchez-Montalva A, Salvador F, et al. Epidemiology and diagnosis of pleural tuberculosis in a low incidence country with high rate of immigrant population: a retrospective study. Int J Infect Dis 2019; 78:34–38.

  • Berger HW, Mejia E. Tuberculous pleurisy. Chest 1973; 63:88-92. 7. Valdes L, Alvarez D, San Jose E, et al. Tuberculous pleurisy: a study of 254 patients. Arch Intern Med 1998; 158: 2017-21.

  • Kim HJ, Lee HJ, Kwon SY, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest 2006; 129: 1253-8.

  • Yılmaz MU, Kumcuoglu Z, Utkaner G, ve ark. Computed tomography fi ndings of tuberculous pleurisy. Int J Tuberc Lung Dis 1998; 2(2): 164-7.

  • Light RW. Tuberculous pleural effusions. In: Light RW, ed. Pleural Diseases. Philadelphia. Williams Wilkins, 2001; 182-95.

  • Porcel JM. Tuberculous pleural effusion. Lung 2009; 187:263-70.

  • Ferrer J. Pleural tuberculosis. Eur Respir J 1997; 10: 942-7.

  • Light RW. Tuberculous pleural effusions. In: Light RW, ed. Pleural disease. Philadelphia: William Wilkins, 2001:182-95.

  • Burgess LJ, Maritz FJ, Le Roux I,et al. Combined use of pleural adenosine deaminase with lymphocyte/ neutrophil ratio. Increased specifi city for the diagnosis of tuberculous pleuritis. Chest. 1996 Feb;109:414-9.

  • Valdes L, Alvarez D, San Jose E. et al. Value of adenosinedeaminase in the diagnosis of tuberculous pleural effusions in young patients in a region of high prevalence of tuberculosis. Thorax. 1995 Jun; 50: 600-3.

  • Jiang J, Shi HZ, Liang QL, et al. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest. 2007 Apr; 131: 1133-41.

  • Krenke R, Safıanowska A, Paplınska M. et al. Pleural fl uid adenosine deaminase and interferon- gamma as diagnostic tools in tuberculous pleurisy. J Physiol Pharmacol. 2008;59: 349-60.

  • Porcel JM. Tuberculous pleural effusion. Lung 2009; 187: 263-70.

  • Porcel-Perez JM, Vives Soto M, Esquerda Serrano A, et al. Cutt off values of biochemical tests on pleural fl uid: their usefulness in differential diagnosis of 1040 patients with pleural effusion. An Med Interna 2004; 21: 113-7.

  • Selçuk T.İnvaziv Tanı Yöntemleri-1 Torasentez, Plevra biyopsisi, Torakoskopi. In: Gözü O, Köktürk O; eds. Plevra Hastalıkları. 1. Baskı. İstanbul: Turgut Yayıncılık; 2003: 92-101.

  • Sakuraba M,Masuda K, Hebisawa A. et al. Thoracoscopic pleural biopsy for tuberculous pleurisy under lokal anesthesia. Ann Thorac Cardiovasc Surg 2006; 12: 245-8).

  • Patiala J. Initial tuberculous pleuritis in the Finnish armed forces in 1939-1945 with special reference to eventual postpleuritic tuberculosis. Acta Tuberc Scand Suppl 1954;36:1-57.

  • World Health Organization. Guidelines for treatment of tuberculosis, Fourth edition, 2010.

  • Treatment of Tuberculosýs: Guidelines for National Programmes. Second Edition 1997 WHO/ TB/97.220

  • Candela A, Andujar J, Hernandez L, et al. Functional sequelae of tuberculous pleurisy in patients correctly treated. Chest 2003; 123: 1996-2000.

  • Bhuniya S, Arunabha DC, Choudhury S, et al. Role of therapeutic thoracentesis in tuberculous pleural effusion. Ann Thorac Med 2012; 7:215.

  • Kwak SM, Park CS, Cho JH, et al. The effects of urokinase instillation therapy via percutaneous transthoracic catheter in loculated tuberculous pleural effusion: a randomized prospective study. Yonsei Med J 2004; 45:822.

  • Cases Viedma E, Lorenzo Dus MJ, González-Molina A, Sanchis Aldás JL. A study of loculated tuberculous pleural effusions treated with intrapleural urokinase. Respir Med 2006; 100:2037.

  • Cao GQ, Li L, Wang YB, et al. Treatment of free-flowing tuberculous pleurisy with intrapleural urokinase. Int J Tuberc Lung Dis 2015; 19:1395.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!